Media Coverage: Asia-Pacific multi-center liver cancer trial SIRveNIB
The multi-center SIRveNIB (AHCC protocol 06) trial led by the National Cancer Center Singapore (NCCS) and the Singapore Clinical Research Institute (SCRI) closed in May 2016. At its close the trial had enrolled 360 patients from 27 centers in 11 member countries of the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group. This pivotal phase III trial compared treatment with Selective Internal Radiation Therapy (SIRT) versus the oral drug sorafenib in patients with locally advanced liver cancer, which is the biggest group of patients with liver cancer. The final results of the study will be presented at the Annual Meeting of ASCO in Chicago by the protocol chair Prof Pierce Chow from NCCS and DukeNUS Medical School at 8.24 am EST on 4th June 2017
Click here to view the media release.